Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GMP Corrective/Preventative Plans Will Get More FDA Attention – Baxter

Executive Summary

FDA's risk-based GMP initiative will require drug manufacturers to become more attentive to corrective and preventative action programs, Baxter Global Regulatory Affairs Director Lisa Skeens, PhD, said

You may also be interested in...



FDA Pharmaceutical Inspectorate Will Have 50 Members By FY 2007

FDA is planning to train a total of 50 investigators for its pharmaceutical inspectorate program by the end of fiscal year 2007

FDA GMP Dispute Resolution Guidance Allows 10 Days To Raise Objections

FDA's dispute resolution draft guidance will allow manufacturers 10 days to challenge FDA inspection findings

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS042460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel